EmploYEd Antithrombotic Therapies in Patients With Acute Coronary Syndromes HOspitalized in iTalian CCUs (EYESHOT-2)

Heart Care Foundation

Status: Completed

Conditions: Acute Coronary Syndrome

Study type: Observational

Funder types: Other

Identifiers

NCT06316128

K26

Details and patient eligibility

About

This registry has the aim to assess the use of different antithrombotic therapies, including untested drug combinations, routinely used during the hospitalization phase, with their timing, route and dose of administration, in consecutive patients discharged with a diagnosis NSTEMI or STEMI in Italian Cardiac care Units (CCUs) during a four-week study period.

Full description

EYESHOT-2 is a prospective, multicenter, observational, nationwide survey of patients discharged with a diagnosis NSTEMI or STEMI admitted to Italian CCUs.

The survey will be designed to include all consecutive patients, who met the eligibility criteria, admitted in hospitals with or without cardiac catheterization laboratories and cardiac surgery facilities during a period of 4 weeks.

Enrollment: 2,806 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All consecutive patients aged 18 years or more, discharged with diagnosis of myocardial infarction (NSTEMI or STEMI) admitted to CCUs undergoing myocardial revascularization (PCI or CABG) or conservative treatment. At presentation, the diagnosis of NSTEMI will be based on the measurement of troponins and assessment of ECG changes, as suggested by European Society of Cardiology (ESC) guidelines; the diagnosis of STEMI will be characterized by an acute chest pain and persistent (>20 min) ST-segment elevation ≥ 1mm in two or more limb leads, or contiguous pre-cordial leads or left bundle branch block.
• Written informed consent signed. Patients who cannot provide the informed consent due to very severe clinical conditions can give their consent some hours/days after admission, when more favourable clinical conditions allow them to receive the appropriate information. Patients having died before giving informed consent may also be included unless the local Institutional Review Board (IRB) does not allow this procedure. In that case, it is strongly suggested to obtain relative(s) agreement through the collect of a signed informed consent.

Exclusion criteria

• Patients with a diagnosis of Unstable Angina,
• Patients developing MI after PCI or CABG,
• MI following non-cardiac surgery or traumatic causes,
• Patients with chest pain without elevation of troponin,
• Patients enrolled in Randomized Controlled Trial (RCTs),
• Patients already enrolled into the study from another CCU